Christian T. Ruff

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Antithrombotic Therapy for Atrial Fibrillation

Gregory Y.H. Lip, Amitava Banerjee, Giuseppe Boriani et al. · CHEST Journal · 2018 · 934 citations · Full text

Medicine, Cardiology, Internal Medicine +14

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Eri Kato, Michael G. Silverman, Ofri Mosenzon et al. · Circulation · 2019 · 563 citations

Medicine, Cardiology, Pharmacology +15

Genetic drivers of heterogeneity in type 2 diabetes pathophysiology

Ken Suzuki, Konstantinos Hatzikotoulas, Lorraine Southam et al. · Nature · 2024 · 513 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

Christian T. Ruff, Robert P. Giugliano, Elliott M. Antman et al. · American Heart Journal · 2010 · 482 citations

Medicine, Cardiology, Pharmacology +14